Clinical Trials Logo
  1. Home
  2. Schizoaffective Disorder
  3. NCT00088465

Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

Schizoaffective Disorder Clinical Trial

Official title:
An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

Clinical Trial Summary

This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot.

Key objectives of the study are to:

- Determine how well intramuscular (IM) olanzapine depot works during long-term treatment,

- Evaluate the safety and tolerability of IM olanzapine depot during long-term treatment,

- Determine the blood levels of IM olanzapine depot in patients during long-term treatment

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00088465
Study type Interventional
Source Eli Lilly and Company
Contact
Status Completed
Phase Phase 3
Start date August 2004
Completion date December 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT01878513 - Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Not yet recruiting NCT04551027 - Assessing the Effect of Compensatory Cognitive Intervention Among People With Severe Mental Illness N/A
Terminated NCT02796144 - MEtformin and Lorcaserin for WeighT Loss in Schizophrenia Phase 4
Completed NCT02901587 - Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder Phase 1
Completed NCT02160249 - RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia) N/A
Recruiting NCT02986490 - Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs N/A
Terminated NCT02234752 - Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia Phase 2
Completed NCT02417142 - Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia Phase 4
Completed NCT02091388 - Bioavailability of LY03004 and Risperdal® Consta® Phase 1
Completed NCT01975584 - Neuroendocrine and Immune Response to Stress in Schizophrenia N/A
Completed NCT01992393 - Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME) N/A
Completed NCT01945333 - Personalized and Scalable Cognitive Remediation Approaches N/A
Terminated NCT02149823 - Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Phase 1
Completed NCT01658150 - Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder N/A
Completed NCT01683539 - Understanding How Cognitive Remediation Works N/A
Completed NCT01292577 - Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia Phase 1/Phase 2